{{flagHref}}

Products

Products
Categories
Blog
Podcast
Application
Document

|

/ {{languageFlag}}

Inquiry

a

Unsealed 188 Rhenium Resin Brachytherapy in Non-Surgical Candidates With Refractory Basal Cell Carcinoma: Clinical Outcomes

Title	Unsealed 188 Rhenium Resin Brachytherapy in Non-Surgical Candidates With Refractory Basal Cell Carcinoma: Clinical Outcomes
Authors	Marco Adriano Chessa, Carlotta Baraldi, Francesco Savoia, Lorenzo Maltoni, Giacomo Clarizio, Federica Filippi, BiancaMaria Piraccini, Emi Dika, Annalisa Pitino, Giovanni Tripepi, Federico Zagni, Lidia Strigari, Luigia Vetrone, Stefano Fanti, Paolo Castellucci
Magazine	Dermatology Practical & Conceptual
Date	04/01/2025
DOI	10.5826/dpc.1502a4933
Introduction	High-dose brachytherapy employing a non-sealed 188Rhenium resin (188Re) presents a novel approach for treating challenging basal cell carcinoma (BCC), achieving effective oncological outcomes while minimising side effects. This retrospective study aims to assess the clinical efficacy of high-dose standardised brachytherapy using unsealed 188Re for managing difficult-to-treat BCCs and to identify risk factors for relapse. Between October 2017 and December 2022, patients with challenging BCCs were selected based on criteria including histologically confirmed cutaneous BCC, invasion thickness under 3 mm, and lesions located in areas where surgery would be difficult or cosmetically undesirable. Patients underwent follow-ups involving videodermoscopy every 4–6 months. The study enrolled 64 patients with 82 high-risk BCCs, showing a 93% complete response rate with relapses averaging 24 months post-treatment. Notably, sclerodermiform BCCs showed a 7-fold higher recurrence risk than nodular BCCs, occurring approximately 12 weeks earlier. The study concludes that high-dose 188Re brachytherapy is a non-invasive, easy-to-perform, and well-tolerated treatment for challenging BCC cases where surgical and other therapeutic approaches are unfeasible.
Quote	Marco Adriano Chessa, Carlotta Baraldi and Francesco Savoia et al. Unsealed 188 Rhenium Resin Brachytherapy in Non-Surgical Candidates With Refractory Basal Cell Carcinoma: Clinical Outcomes. Dermatol Pract Concept. 2025. Vol. 15(2). DOI: 10.5826/dpc.1502a4933
Materials	Chemical Compounds
Industry	Pharmaceutical Industry

Related papers

Loading... Please wait...

Publish your research and articles on the SAM website

Disclaimer

This site only provides metadata for academic works to enable users to easily find relevant information. For full access to the works, please use the DOI to visit the original publisher's website. The data comes from publicly accessible scientific databases and complies with the terms of use of these platforms. If you have any concerns regarding copyright, please contact us. We will address them immediately.

Success! You are now subscribed.

You have successfully subscribed! Check your inbox soon to receive great emails from this sender.

Copyright © 1994-2025 Stanford Advanced Materials owned by Oceania International LLC, all rights reserved